To access full text you may have to log in to your NHS Athens account (click here to register for free). If full text is not available then please email us to request a copy.
Links may not work in older versions of Internet Explorer, please use an alternative browser.
The report reveals that nationally just 20 per cent of patients who see a GP with suspected rheumatoid and early inflammatory arthritis are referred to specialist services within the three-day limit recommended by the National Institute for Health and Care Excellence (NICE).
Methotrexate monotherapy and methotrexate combination therapy with traditional and biologic disease modifying anti-rheumatic drugs for rheumatoid arthritis: A network meta-analysis Authors' conclusions: We found moderate to high quality evidence that combination therapy with methotrexate + sulfasalazine+ hydroxychloroquine (triple therapy) or methotrexate + most biologic DMARDs or tofacitinib were similarly effective in controlling disease activity and generally well tolerated in methotrexate-naïve patients or after an inadequate response to methotrexate. Methotrexate + some biologic DMARDs were superior to methotrexate in preventing joint damage in methotrexate-naïve patients, but the magnitude of these effects was small over one year.
Do you have any research needs?
Please contact your Rheumatology Clinical Librarian, Pip Divall on 0116 250 2309 or Pip.Divall@uhl-tr.nhs.uk
